Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.

Abstract

In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

• Authors: David L Thomas, John G Bartlett, Marion G Peters, Kenneth E Sherman, Mark S Sulkowski, Paul A Pham
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 54 Issue 7 Pg. 979-83 (Apr 2012) ISSN: 1537-6591 [Electronic] United States
• PMID: 22173234 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antiviral Agents
• Oligopeptides
• Protease Inhibitors
• telaprevir
• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
• Proline

Topics

• Antiviral Agents (administration & dosage, adverse effects, pharmacokinetics)
• Genotype
• Guidelines as Topic
• HIV Infections (complications)
• Hepacivirus (classification, genetics)
• Hepatitis C, Chronic (drug therapy, virology)
• Humans
• Oligopeptides (administration & dosage, adverse effects, pharmacokinetics)
• Proline (administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics)
• Protease Inhibitors (administration & dosage, adverse effects, pharmacokinetics)
• United States